There is a solution to the MRSA challenge...

Along with MRSA, many significant infection-causing bacteria (Cdiff for example) in the world are also becoming resistant to the most commonly prescribed antimicrobial treatments.  Antimicrobial resistance occurs when bacteria change or adapt in a way that allows them to survive in the presences of antibiotics designed to kill them.  The some cases, bacteria become so resistant that no available antibiotics are effective against them.  People infected with antibiotic-resistant organisms like MRSA and Cdiff are likely to have longer and more expensive hospital stays, and may be more likely to die as a result of the infection.  When the drug of choice for treating their infection doesn't work, they require treatment with second- or third-choice medicines that may be less effective, more toxic and more expenses.  

But there is a new weapon in the fight against MRSA and other antibiotic-resistant strains of bacteria.  The Microcyn Technology  (www.oculusis.com/us/technology) is a safe-as-water topical anti-infective  that quickly eradicates a broad range of pathogens including MRSA, VRE, Cdiff and even chlorine-resistant strains.  Dual-action in nature, in addition to killing the infection, Microcyn also accelerates the wound-healing process by reducing inflammation in the wound and increasing nutrient-rich blood and oxygen flow to the wound site.  Twenty-five clinical studies have demonstrated Microcyn to be both safe and effective in killing pathogens. There's an excellent MD discussion of this new technology at YouTube: http://www.youtube.com/watch?v=sAiWWNCfYH4

Microcyn is commercially available in the US under three FDA clearances and is also available for animals at www.vetericyn.com.